Comparison of Metabolic Changes in Osteoarthritis and Rheumatoid Arthritis Mouse Models (2018) Huelser ML, Sauermilch HM, Schreiyaeck C, Luo Y, Bozec A, Schett G, Mueller-Ladner U, Neumann E Conference contribution Long Noncoding RNA H19X Is a Key Regulator of Apoptosis and Proliferation of Fibroblasts in Systemic Sclerosis and Other TGF beta-riven Fibrotic Diseases (2017) Pachera E, Wunderlin A, Assassi S, Salazar G, Bertoncelj MF, Dobrota R, Brock M, et al. Conference contribution Important Role of CD11c+Dendtritic Cells in Inflammatory Arthritis (2017) Puchner A, Saferding V, Bonelli M, Leiss H, Krönke G, Pfeifle R, Smolen JS, et al. Conference contribution Increased Plasma Levels of Hsp90 Are Associated with More Severe Organ Involvement in Patients with Systemic Sclerosis (2017) Storkanova H, Oreska S, Spiritovic M, Pavelka K, Vencovsky J, Distler J, Senolt L, et al. Conference contribution Fra-2 Overexpression Leads to Systemic Autoimmunity By Affecting IL2 Dependent Treg Homeostasis (2017) Renoux F, Stellato M, Impellizzieri D, Vogetseder A, Blyszczuk P, Huang R, Subramaniam A, et al. Conference contribution Dipeptidyl-Peptidase-4 (DPP4) Promotes Fibroblast Activation and Is a Potential Molecular Target for Treatment of Fibrosis (2017) Soare A, Gyoerfy H, Matei AE, Dees C, Chen CW, Ramming A, Schett G, Distler J Conference contribution Baseline Structural Damage Predicts Response to Abatacept in Patients with Psoriatic Arthritis: A Post Hoc Analysis from a Phase III Study (2017) Schett G, Lehman T, Ahmad HA, Johnsen A, Banerjee S, Mease PJ Conference contribution Adipocytokines in an Osteoarthritis Mouse Model (2017) Huelser ML, Schreiyaeck C, Luo Y, Bozec A, Schett G, Neumann E, Mueller-Ladner U Conference contribution Consistent Safety Profile with up to 4 Years of Apremilast Treatment: Analysis of Data from 1,493 Subjects with Psoriatic Arthritis in 3 Large, Phase III, Long-Term Studies (2017) Mease PJ, Gladman DD, Gomez-Reino JJ, Hall S, Kavanaugh A, Lespessailles E, Schett G, et al. Conference contribution Prediction of Response to Certolizumab-Pegol in Rheumatoid Arthritis By Functional MRI of the Brain - an Interim Analysis of an Ongoing Investigator Initiated Phase III Trial (2017) Schenker H, Heß A, Konerth L, Sergeeva M, Prade J, Kleyer A, Reiser M, et al. Conference contribution